<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijerph-17-05904-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijerph-17-05904-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>Potential therapeutic targets associated with macrophage activation under clinical trials [
   <xref rid="B93-ijerph-17-05904" ref-type="bibr">93</xref>,
   <xref rid="B94-ijerph-17-05904" ref-type="bibr">94</xref>,
   <xref rid="B95-ijerph-17-05904" ref-type="bibr">95</xref>].
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Type</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Role of Target</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Number</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Tocilizumab</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Anti-IL-6 receptor</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">IL-6 signaling process</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pro-inflammatory</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NCT04306705; NCT04346355; NCT04320615; NCT04317092; NCT04335071; 
     <sup>a</sup> NCT04331808
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">No drug approved</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Various</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">TLR4–TRIF signaling</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pro-inflammatory</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Emapalumab</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Anti-IFNγ</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">IFNγ</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pro-inflammatory</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NCT04324021</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Tofacitinib</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">JAK1/JAK3 inhibitor</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">JAK-STAT signaling</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pathway mediates cytokine signaling</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">
     <sup>a</sup> NCT04340232; 
     <sup>a</sup> NCT04320277
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Cenicriviroc (not approved)</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">CCR2 and CCR5 antagonist</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">CCR2</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Promotes monocyte recruitment in tissues</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Clinical trial in progress</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Sargramostim</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">GM-CSF</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">GM-CSF signaling</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pro- inflammatory; repairing lung tissues</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NCT04326920</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Fliximab; adalimumab; golimumab</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Anti-TNF</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">TNF signaling</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Pro- inflammatory</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anakinra</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1 receptor antagonist</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1β signaling</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pro-inflammatory</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT04339712; NCT04324021; NCT04330638; 
     <sup>a</sup> NCT04341584
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Data from ClinicalTrials.gov. IFNγ, interferon-γ; JAK, Janus kinase; CCR2, CC chemokine receptor 2; CCR5, CC chemokine receptor 5; STAT, signal transducer and activator of transcription; GM-CSF, granulocyte-macrophage colony-stimulating factor; NA, not applicable; TLR, Toll-like receptor; 
    <sup>a</sup> clinical trials not yet recruiting at time of publication.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
